Supplementary Table 1.
Characteristics of the Enrolled Cohort
| Characteristics | Value |
|---|---|
| Total number | 103 |
| Female sex, n (%) | 50 (48) |
| Age, y, median (range) | 40 (22–50) |
| Disease, n (%) | |
| Crohn’s disease | 63 (61) |
| Ulcerative colitis | 40 (39) |
| Biologic treatment, n (%) | |
| Infliximab | 36 (35) |
| Adalimumab | 44 (43) |
| Vedolizumab | 12 (11) |
| Ustekinumab | 8 (8) |
| Golimumab | 3 (3) |
| Concomitant immunosuppressive treatment, n (%) | |
| Prednisone | 2 (2) |
| Azathioprine | 21 (20) |
| Treatment regimen, n (%) | |
| Induction | 11 (11) |
| Regular | 88 (85) |
| Delayed | 4 (4) |
| COVID-19 reported symptoms, n (%) | 13 (13) |
| Fever | 10 (9) |
| Cough | 6 (6) |
| Dysgeusia/anosmia | 5 (5) |
| Contacts with COVID-19–ascertained patients, n (%) | 4 (4) |